DIFFUSE INTRINSIC PONTINE GLIOMA

This early-phase study tests a vaccine called SurVaxM in 35 children with certain brain tumors that have come back or are hard to treat. The vaccine is designed to teach the immune system to find and destroy tumor cells that have a protein called survivin. The goal is to see if i…

This study tests the Optune device, a wearable cap that creates low-intensity electric fields to disrupt cancer cell growth, in children with aggressive brain tumors. One group of children with recurrent high-grade glioma or ependymoma will use the device alone to see if it's fea…

This early-phase study tests a new treatment for glioblastoma, an aggressive brain cancer. The approach uses a patient's own immune cells, modified in the lab to better recognize and attack the tumor, combined with chemotherapy. The main goal is to check the safety of this therap…

This early-phase trial tests whether focused ultrasound can temporarily open the blood-brain barrier in children with a rare, aggressive brain tumor called DIPG. The goal is to let the chemotherapy drug doxorubicin reach the tumor more effectively. Only 10 children aged 5 to 18 w…

This study tests whether a special ultrasound device can safely open the blood-brain barrier in children with a rare, aggressive brain tumor called DIPG. By temporarily allowing the chemotherapy drug doxorubicin to reach the tumor, researchers hope to improve treatment. The study…

This early-phase trial is testing the safety of an experimental drug called PTC596 (Unesbulin) when given alongside radiation therapy to children and young adults newly diagnosed with diffuse intrinsic pontine glioma (DIPG) or high-grade glioma. The study aims to find the safest …

This study tests whether adding an experimental drug called indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers. The drug aims to boost the body's immune system to fight tumors more effectively. The trial includes children wi…

This early-stage trial tests a new treatment called SC-CAR4BRAIN for children and young adults with certain aggressive brain tumors, including DIPG and DMG. The treatment involves taking a patient's own immune T cells, engineering them in a lab to recognize and attack tumor cells…

This phase 2 study tests two experimental drugs, atengenal and astugenal, in people with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. The trial aimed to enroll up to 100 participants across five age and treatment groups, but only 1 person joined bef…